# OnCo record pixantrone (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pixantrone/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pixantrone" ;
  schema:name "Pixantrone"@en ;
  schema:alternateName "BBR 2778"@en, "Pixantrone dimaleate"@en, "Pixuvri" ;
  schema:description "Pixantrone is an anthracycline-like drug engineered to spare the heart. The European Union authorised it in 2012 as a single agent for adults with aggressive B-cell lymphoma that had relapsed several times; the authorisation expired in June 2024 when the company did not renew it."@en ;
  schema:url <https://onco.cc/drugs/pixantrone/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pixantrone> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri>, <https://en.wikipedia.org/wiki/Pixantrone>, <https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201855> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Aza-anthracenedione cytotoxic, intravenous" ;
  onco:approval "EU 2012: Multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, single agent (conditional)" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/top2a/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/> ;
  onco:companies <https://onco.cc/companies/servier/> ;
  onco:trials <https://onco.cc/trials/nct01086605/>, <https://onco.cc/trials/nct03458260/> .